header logo image

BRIEF-Uniqure Announces License Agreement With CSL Behring To Commercialize Hemophilia B Gene Therapy – Reuters

June 25th, 2020 6:42 pm

June 24 (Reuters) - Uniqure NV:

* UNIQURE ANNOUNCES LICENSE AGREEMENT WITH CSL BEHRING TO COMMERCIALIZE HEMOPHILIA B GENE THERAPY

* UNIQURE NV - UNIQURE ELIGIBLE TO RECEIVE MORE THAN $2 BILLION, INCLUDING $450 MILLION IN UPFRONT CASH

* UNIQURE NV - CO ELIGIBLE TO RECEIVE $1.6 BILLION IN MILESTONE PAYMENTS, AND DOUBLE-DIGIT ROYALTIES RANGING UP TO A LOW-TWENTIES PERCENTAGE OF NET SALES

* UNIQURE NV - LICENSING AGREEMENT PROVIDES CSL BEHRING EXCLUSIVE GLOBAL RIGHTS TO ETRANACOGENE DEZAPARVOVEC

* UNIQURE NV - CLINICAL DEVELOPMENT AND REGULATORY ACTIVITIES PERFORMED BY UNIQURE UNDER AGREEMENT WILL BE REIMBURSED BY CSL BEHRING

* UNIQURE NV - CSL BEHRING WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS & COMMERCIALIZATION OF ETRANACOGENE DEZAPARVOVEC

* UNIQURE NV - CO PLANS TO DE-PRIORITIZE ITS RESEARCH PROGRAM OF AMT-180 FOR PATIENTS WITH HEMOPHILIA A

* UNIQURE NV - EXPECT TRANSACTION TO PROVIDE CO WITH SIGNIFICANT FINANCIAL RESOURCES TO ADVANCE & EXPAND PIPELINE OF GENE THERAPY CANDIDATES Source text for Eikon: Further company coverage:

See original here:
BRIEF-Uniqure Announces License Agreement With CSL Behring To Commercialize Hemophilia B Gene Therapy - Reuters

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick